IE981006A1

IE981006A1 - Glucosamine hydrochloride drink

Info

Publication number: IE981006A1
Application number: IE981006A
Authority: IE
Inventors: Gerard Finn; John Anthony Bott-Walters
Original assignee: Gerard Finn
Priority date: 1998-12-02
Filing date: 1998-12-02
Publication date: 2000-06-14

Abstract

This invention relates to a formulation and manufacturing process combining the additive effects of branched chain amino acids, maltodextrins, salts, glucosamine hydrochloride and chondroitin sulphate for manufacture in the food industry for the purpose of: increasing bioavailability, palatability, solubility, and reducing the emetic effect of glucosamine in combination as glucosamine hydrochloride with chondroitin sulphate amelioration and or prevention of exercise-induced inflammation through consumption of a highly soluble, non-emetic, highly palatable drink.

Description

This invention relates to a formulation and manufacturing process combining the additive effects of branched chain amino acids, maltodextrins, salts, glucosamine hydrochloride and chondroitin sulphate for manufacture in the food industry for the purpose of: increasing bioavailability, palatability, solubility, and reducing the emetic effect of glucosamine in combination as glucosamine hydrochloride with chondroitin sulphate amelioration and or prevention of exercise-induced inflammation through consumption of a highly soluble, nonemetic, highly palatable drink.

J. Increasing bioavailability, palazability, solubility, and reducing the emetic effect of glucosamine in combination as glucosamine hydrochloride with chondroitin sulphate Currently, various combination of glucosamine sulphate and chondroitin sulphate are available in tablet form. The tablets are large, typically greater than 1000 mg, and are associated with poor taste, nausea, low bioavailability and difficulty with regards consumption by older takers. For medical efficacy the tablets have to be consumed twice daily for a period of no less than 30 days. The tablet's properties make compliance with this regimen extremely difficult.

The present invention describes a process whereby a combination of branched chain amino acids, maltodextrins, salts, glucosamine hydrochloride and chondroitin sulphate is manufactured such that it is soluble without clumping ί :;:τ η Τίκ Silfoae - 2 and Improves bioavailability of glucosamine over that derived from glucosamine sulphate and chondriotin sulphate in hot or cold water and does not have the contraindication of nausea. 2. Amelioration and or prevention of exercise-induced inflammation through consumption of a highly soluble, nonemetic, highly palatable drink The use of a combination of branched chain amino acids, raaltodextrins, salts, glucosamine hydrochloride and chondroitin sulphate taken as a drink prior to and or during exercise reduces the rate of post-exercise inflammation in those unaccustomed to exercise and represents an alternative to extended post-exercise stretching regimes and or use of mild non-steriodal antiinflammatories.

According to the present invention there is provided an aqueous solution typically 250 - 300 ml in volume containing: a) Maltodextrin preferably at 4 to 15 Dextrose Equivalents (DE), more preferably at 8 to 12 DE at 3 to 10% (w/v,, even more preferably at 4 to 6% (w/v,, and most preferred at 4,5% (w/v); b) L-leucine at 0.025 to 5 grammes in total, more preferred 0.025 to 0.75g in total and most preferred at 0.05g in total; c) L-isoleucine at 0.01 to 5g in total, more preferred 0.01 to O.lSg in total and most preferred 0.025g in total; d) L-valine 0.01 to 5g in total, more preferred 0.01 to 0.75g in total and most preferred 0.025g in total; e) Preferably L-ascorbic acid at 0.06g in total; - 3 f) Preferably anhydrous citric acid at 0.4 g in total; g) Glucosamine hydrochloride preferably at 0-5 to 2.0 grammas, more preferred at 0.75 to 1.6 grammes and most preferred at 1.0 to 1.5 grammes; and h) Chondroitin sulphate at preferably 0.1 to 0.4 grammes, more preferred at 0.1 to 0.3 grammes, and most preferred at 0.25g.

Plus any flavours, preservative or additive necessary to comply with food safety regulations and/or to improve io taste.

The invention also provides dry formulations which, when dissolved in about 250-300 ml of water, provide the solution described above.

Claims

1. A Liquid preparation containing in a liquid volume of 250-300 ml the following constituents: a) Maltodextrin preferably at 4 to 15 Dextrose 5 Equivalents (DE), more preferably at 8 to 12 DE at 3 to 10% (w/v), even more preferably at 4 tc 6% (w/v), and most preferred at 4.5% (w/v); b) L-leucine at 0.025 to 5 grammes in total, more preferred 0.025 to 0.75g in total and most preferred 10 at 0.05g in total; c) L-isoleucine at 0.01 to Sg in total, more preferred 0.01 to 0.75g in total and most preferred 0.025g in total; d) L-valine 0.01 to Sg in total, more preferred 0.01 to is 0.75g in total and mo3t preferred 0.025g in total; e) Preferably L-ascorbic acid at 0.06g in total; f) Preferably anhydrous citric acid at 0.4 g in total; g) Glucosamine hydrochloride preferably at 0.5 to 2.0 grammes, more preferred at 0.75 to 1.6 grammes and 20 most preferred at 1.0 to 1.5 grammes; and h) Chondroitin sulphate at preferably 0.1 to 0.4 grammes, more preferred at 0.1 to 0.3 grammes, and most preferred at 0.25g.

2. A preparation according to claim 1 which is an 25 aqueous solution of the constituents.

3. A preparation according to claim 1 or 2 additionally containing a sweetening/colouring/flavouring/ preserving and/or carbonation agent.

4. A preparation according to claim 3 containing about 30' 50 mg Aspartame.

5. A preparation according to any preceding claim wherein the maltodextrin is in part or completely substituted with longer or shorter polymeric maltodextrin. 5

6. A preparation according to any preceding claim wherein the BCAAs are substituted in part or completely with their pharmacologically or physiologically active analogues.

7. A dry formulation which, when dissolved or suspended io in about 250-300 ml of liquid, provides a preparation according to any preceding claim.

8. A dry formulation according to claim 7 in powder form.

9. A dry formulation according to claim 7 in particulate 15 form.

10. A method for making a dry formulation according to claim 8 which comprises blending said dry constituents .

11. A method for making a dry formulation according to 20 claim 9 which comprises mixing said dry constituents in particulate form.

12. Ose of a preparation or formulation according to any one of claims 1 to 9 in a method for increasing bioavailability, palatability, solubility, and 25 reducing the emetic effect of glucosamine in combination as glucosamine hydrochloride with chondroitin sulphate.

13. Use of a preparation or formulation according to any one of claims 1 to 9 in a method for amelioration and or prevention of exercise-induced inflammation through consumption of a highly soluble, non-emetic, 5 highly palatable drink.

14. A method of increasing bioavailability, palatability, solubility, and reducing the emetic effect of glucosamine in combination as glucosamine hydrochloride with chondroitin sulphate which io comprises administration of a preparation according to any one of claims 1 to 6.

15. A method of amelioration and or prevention of exercise-induced inflammation through consumption of a highly soluble, non-emetic, highly palatable drink 15 which comprises administration of a preparation according to any one of claims 1 to 6.